Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 09/01/26
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?Zacks Investment Research • 09/01/26
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV InfectionZacks Investment Research • 08/28/26
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsCNBC • 08/27/26
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex RegimensBusiness Wire • 08/27/26
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor ConferencesBusiness Wire • 08/26/26
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy LiftingThe Motley Fool • 08/26/26
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBCZacks Investment Research • 08/25/26
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 StatusBusiness Wire • 08/24/26
Robbins LLP Encourages ITOC Stockholders Who Lost Money Investing in iTonic Holdings Ltd. to Contact the Firm for Information About Leading the Class ActionNewsfile Corp • 08/19/26
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022The Motley Fool • 08/19/26
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.The Motley Fool • 08/18/26
Court rules companies can't import Gilead medications from overseas in blow to AFP health programsCNBC • 08/14/26
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)Seeking Alpha • 08/10/26
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook RaisedZacks Investment Research • 08/05/26
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial ResultsBusiness Wire • 08/05/26
Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/05/26